Madrigal Pharmaceuticals Inc (MDGL) is a clinical-stage biopharmaceutical company that focuses on developing therapies for metabolic and liver diseases. The company's lead drug candidate, MGL-3196, is an orally administered, small-molecule liver-directed thyroid hormone receptor beta (THR-β) agonist that is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and familial hypercholesterolemia (FH). NASH is a progressive form of liver disease that is closely linked to obesity and type 2 diabetes, while FH is an inherited disorder that leads to high levels of low-density lipoprotein (LDL) cholesterol in the blood.
Madrigal's pipeline also includes MGL-3745, an oral inhibitor of acetyl-CoA carboxylase (ACC), which is being evaluated as a potential treatment for NASH and other metabolic diseases. In addition, the company is exploring the potential of THR-β agonists in other indications, including primary biliary cholangitis and adrenoleukodystrophy.
Madrigal Pharmaceuticals was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals Inc (MDGL) is a clinical-stage biopharmaceutical company that focuses on developing therapies for metabolic and liver diseases. The company's lead drug candidate, MGL-3196, is an orally administered, small-molecule liver-directed thyroid hormone receptor beta (THR-β) agonist that is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and familial hypercholesterolemia (FH). NASH is a progressive form of liver disease that is closely linked to obesity and type 2 diabetes, while FH is an inherited disorder that leads to high levels of low-density lipoprotein (LDL) cholesterol in the blood.